People are battling ‘ghost fat’ after losing weight on GLP-1s
Many Americans are experiencing a phenomenon called 'ghost fat' after significant weight loss from GLP-1 drugs like Wegovy and Zepbound. This condition leads individuals to perceive themselves as larger than they actually are, creating a disconnect between their physical appearance and self-image. Experts suggest that cognitive behavioral therapy may help individuals align their self-perception with their new bodies.
- ▪One in eight US adults is using GLP-1 drugs to lose weight.
- ▪Users typically lose between 15% and 20% of their body weight within a year.
- ▪Nearly two-thirds of women studied post-bariatric surgery still perceived themselves as obese despite weight loss.
New York Post files mainly under news. We currently carry 11,003 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | New York Post |
| Canonical URL | https://nypost.com/2026/06/06/health/people-are-battling-ghost-fat-after-losing-weight-on-glp-1s/ |
| Publication time | Sat, 06 Jun 2026 10:30:02 -0400 |
| Retrieval time | 2026-06-06T14:31:26.263Z |
| Last seen | 2026-06-06T15:06:21.876Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | FmhMLrhmg7Ww |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Mental Health People are battling ‘ghost fat’ after losing weight on GLP-1s By McKenzie Beard Published June 6, 2026, 10:30 a.m. ET See more of our coverage in your search results. Add The New York Post on Google Sometimes, seeing isn’t believing. Across the country, Americans are losing weight faster than ever thanks to blockbuster obesity drugs like Wegovy and Zepbound, with roughly one in eight US adults now turning to GLP-1s to slim down. But for some users, the dramatic physical changes come with an unexpected psychological twist. 3 Users of GLP-1 drugs tend to shed between 15% and 20% of their body weight within one year.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
